PP
NBIX icon

Paloma Partners’s Neurocrine Biosciences NBIX Stock Holding History

Paloma Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,468
Closed -$240K – 1624
2021
Q2 		$240K Buy
+2,468
New +$237K ﹤0.01% 1442
2019
Q4 		– Sell
-12,354
Closed -$1.11M – 2383
2019
Q3 		$1.11M Buy
+12,354
New +$1.15M 0.02% 686
2019
Q2 		– Sell
-11,680
Closed -$1.03M – 2045
2019
Q1 		$1.03M Buy
+11,680
New +$976K 0.03% 714
2018
Q4 		– Sell
-24,345
Closed -$2.99M – 1615
2018
Q3 		$2.99M Buy
+24,345
New +$2.76M 0.05% 313
2018
Q2 		– Sell
-14,713
Closed -$1.22M – 2011
2018
Q1 		$1.22M Sell
14,713
-19,432
-57% -$1.64M 0.02% 873
2017
Q4 		$2.65M Buy
34,145
+8,557
+33% +$584K 0.04% 535
2017
Q3 		$1.57M Buy
+25,588
New +$1.35M 0.02% 890
2017
Q2 		– Sell
-39,539
Closed -$1.71M – 2354
2017
Q1 		$1.71M Sell
39,539
-445
-1% -$19.1K 0.02% 887
2016
Q4 		$1.55M Buy
39,984
+19,708
+97% +$892K 0.02% 853
2016
Q3 		$1.03M Sell
20,276
-131,447
-87% -$6.55M 0.01% 997
2016
Q2 		$6.9M Buy
151,723
+123,023
+429% +$5.66M 0.08% 172
2016
Q1 		$1.14M Buy
+28,700
New +$1.14M 0.02% 800
2015
Q4 		– Sell
-8,949
Closed -$356K – 1853
2015
Q3 		$356K Buy
+8,949
New +$433K 0.01% 1202
2014
Q4 		– Sell
-18,690
Closed -$293K – 1301
2014
Q3 		$293K Buy
+18,690
New +$279K 0.01% 723
2013
Q3 		– Sell
-63,877
Closed -$855K – 1101
2013
Q2 		$855K Buy
+63,877
New +$785K 0.05% 302

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Paloma Partners's NBIX Position: Q3 2021 in Review

Paloma Partners sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 2,468 shares — an estimated $240K sold.

Paloma Partners first reported a position in NBIX in Q2 2013 and held it in 15 quarters. The position peaked at $6.9M in Q2 2016. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Paloma Partners reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Paloma Partners sold 2,468 Neurocrine Biosciences shares in Q3 2021, an estimated $240K.
  • Paloma Partners first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 15 quarters.
  • Paloma Partners's Neurocrine Biosciences position peaked at $6.9M in Q2 2016.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Paloma Partners's 13F filing for Q3 2021, filed 15 Nov 2021.